224 related articles for article (PubMed ID: 33093009)
1. Outcomes of VD-PACE With Immunomodulatory Agent as a Salvage Therapy for Relapsed/Refractory Multiple Myeloma.
Abdallah AO; Sigle M; Mohyuddin GR; Coggins E; Remker C; Shune L; Mahmoudjafari Z; McGuirk J; Ganguly S
Clin Lymphoma Myeloma Leuk; 2021 Feb; 21(2):e220-e226. PubMed ID: 33093009
[TBL] [Abstract][Full Text] [Related]
2. A comparison of salvage infusional chemotherapy regimens for recurrent/refractory multiple myeloma.
Griffin PT; Ho VQ; Fulp W; Nishihori T; Shain KH; Alsina M; Baz RC
Cancer; 2015 Oct; 121(20):3622-30. PubMed ID: 26149422
[TBL] [Abstract][Full Text] [Related]
3. Outcomes of Daratumumab, Pomalidomide, and Dexamethasone, Followed by High-dose Chemotherapy and Autologous Stem Cell Transplantation, in Patients With Relapsed/Refractory Multiple Myeloma.
Abdallah AO; Mohyuddin GR; Mahmoudjafari Z; Atrash S; Kawsar H; Sigle M; Shune L; McGuirk J; Ganguly S
Clin Lymphoma Myeloma Leuk; 2021 Feb; 21(2):e212-e219. PubMed ID: 33051166
[TBL] [Abstract][Full Text] [Related]
4. Carfilzomib-Dexamethasone Versus Bortezomib-Dexamethasone in Relapsed or Refractory Multiple Myeloma: Updated Overall Survival, Safety, and Subgroups.
Orlowski RZ; Moreau P; Niesvizky R; Ludwig H; Oriol A; Chng WJ; Goldschmidt H; Yang Z; Kimball AS; Dimopoulos M
Clin Lymphoma Myeloma Leuk; 2019 Aug; 19(8):522-530.e1. PubMed ID: 31160237
[TBL] [Abstract][Full Text] [Related]
5. Bortezomib, doxorubicin, and dexamethasone combination therapy followed by thalidomide and dexamethasone consolidation as a salvage treatment for relapsed or refractory multiple myeloma: analysis of efficacy and safety.
Lee SS; Suh C; Kim BS; Chung J; Joo YD; Ryoo HM; Do YR; Jin JY; Kang HJ; Lee GW; Lee MH; Shim H; Kim K; Yoon SS; Bang SM; Kim HY; Lee JJ; Park J; Lee DS; Lee JH;
Ann Hematol; 2010 Sep; 89(9):905-12. PubMed ID: 20349060
[TBL] [Abstract][Full Text] [Related]
6. Analysis of the Efficacy of Thalidomide Plus Dexamethasone-Based Regimens in Patients With Relapsed/Refractory Multiple Myeloma Who Received Prior Chemotherapy, Including Bortezomib and Lenalidomide: KMM-166 Study.
Jung KS; Kim K; Kim HJ; Kim SH; Lee JO; Kim JS; Lee JJ; Eom HS; Min CK; Shin HJ
Clin Lymphoma Myeloma Leuk; 2020 Feb; 20(2):e97-e104. PubMed ID: 31831372
[TBL] [Abstract][Full Text] [Related]
7. Multiagent therapy with pomalidomide, bortezomib, doxorubicin, dexamethasone, and daratumumab ("Pom-PAD-Dara") in relapsed/refractory multiple myeloma.
Zhou X; Steinhardt MJ; Grathwohl D; Meckel K; Nickel K; Leicht HB; Krummenast F; Einsele H; Rasche L; Kortüm KM
Cancer Med; 2020 Aug; 9(16):5819-5826. PubMed ID: 32608149
[TBL] [Abstract][Full Text] [Related]
8. Final analysis of a phase 1/2b study of ibrutinib combined with carfilzomib/dexamethasone in patients with relapsed/refractory multiple myeloma.
Chari A; Cornell RF; Gasparetto C; Karanes C; Matous JV; Niesvizky R; Lunning M; Usmani SZ; Anderson LD; Chhabra S; Girnius S; Shustik C; Stuart R; Lee Y; Salman Z; Liu E; Valent J
Hematol Oncol; 2020 Aug; 38(3):353-362. PubMed ID: 32053229
[TBL] [Abstract][Full Text] [Related]
9. Panobinostat plus bortezomib and dexamethasone versus placebo plus bortezomib and dexamethasone in patients with relapsed or relapsed and refractory multiple myeloma: a multicentre, randomised, double-blind phase 3 trial.
San-Miguel JF; Hungria VT; Yoon SS; Beksac M; Dimopoulos MA; Elghandour A; Jedrzejczak WW; Günther A; Nakorn TN; Siritanaratkul N; Corradini P; Chuncharunee S; Lee JJ; Schlossman RL; Shelekhova T; Yong K; Tan D; Numbenjapon T; Cavenagh JD; Hou J; LeBlanc R; Nahi H; Qiu L; Salwender H; Pulini S; Moreau P; Warzocha K; White D; Bladé J; Chen W; de la Rubia J; Gimsing P; Lonial S; Kaufman JL; Ocio EM; Veskovski L; Sohn SK; Wang MC; Lee JH; Einsele H; Sopala M; Corrado C; Bengoudifa BR; Binlich F; Richardson PG
Lancet Oncol; 2014 Oct; 15(11):1195-206. PubMed ID: 25242045
[TBL] [Abstract][Full Text] [Related]
10. Efficacy of VDT PACE-like regimens in treatment of relapsed/refractory multiple myeloma.
Lakshman A; Singh PP; Rajkumar SV; Dispenzieri A; Lacy MQ; Gertz MA; Buadi FK; Dingli D; Hwa YL; Fonder AL; Hobbs M; Hayman SR; Zeldenrust SR; Lust JA; Russell SJ; Leung N; Kapoor P; Go RS; Lin Y; Gonsalves WI; Kourelis T; Warsame R; Kyle RA; Kumar SK
Am J Hematol; 2018 Feb; 93(2):179-186. PubMed ID: 29067723
[TBL] [Abstract][Full Text] [Related]
11. DCEP as a bridge to ongoing therapies for advanced relapsed and/or refractory multiple myeloma.
Yuen HLA; Low MSY; Fedele P; Kalff A; Walker P; Bergin K; Coutsouvelis J; Grigoriadis G; Spencer A
Leuk Lymphoma; 2018 Dec; 59(12):2842-2846. PubMed ID: 29616871
[TBL] [Abstract][Full Text] [Related]
12. A comparison of the efficacy of immunomodulatory-free regimens in relapsed or refractory multiple myeloma: a network meta-analysis.
Weisel K; Sonneveld P; Spencer A; Beksac M; Rizzo M; Xu Y; Fahrbach K; Gaudig M; Slavcev M; Dearden L; Lam A
Leuk Lymphoma; 2019 Jan; 60(1):151-162. PubMed ID: 30407092
[TBL] [Abstract][Full Text] [Related]
13. Pomalidomide plus low-dose dexamethasone versus high-dose dexamethasone alone for patients with relapsed and refractory multiple myeloma (MM-003): a randomised, open-label, phase 3 trial.
Miguel JS; Weisel K; Moreau P; Lacy M; Song K; Delforge M; Karlin L; Goldschmidt H; Banos A; Oriol A; Alegre A; Chen C; Cavo M; Garderet L; Ivanova V; Martinez-Lopez J; Belch A; Palumbo A; Schey S; Sonneveld P; Yu X; Sternas L; Jacques C; Zaki M; Dimopoulos M
Lancet Oncol; 2013 Oct; 14(11):1055-1066. PubMed ID: 24007748
[TBL] [Abstract][Full Text] [Related]
14. Single-agent daratumumab in very advanced relapsed and refractory multiple myeloma patients: a real-life single-center retrospective study.
Jullien M; Trudel S; Tessoulin B; Mahé B; Dubruille V; Blin N; Gastinne T; Bonnet A; Lok A; Lebourgeois A; Peterlin P; Garnier A; Chevalier P; Guillaume T; Thomaré P; Le Gouill S; Moreau P; Touzeau C
Ann Hematol; 2019 Jun; 98(6):1435-1440. PubMed ID: 30874850
[TBL] [Abstract][Full Text] [Related]
15. Low-dose thalidomide for multiple myeloma: interim analysis of a compassionate use program.
Steurer M; Spizzo G; Mitterer M; Gastl G
Onkologie; 2004 Apr; 27(2):150-4. PubMed ID: 15138347
[TBL] [Abstract][Full Text] [Related]
16. Pomalidomide, bortezomib, and dexamethasone for patients with relapsed or refractory multiple myeloma previously treated with lenalidomide (OPTIMISMM): a randomised, open-label, phase 3 trial.
Richardson PG; Oriol A; Beksac M; Liberati AM; Galli M; Schjesvold F; Lindsay J; Weisel K; White D; Facon T; San Miguel J; Sunami K; O'Gorman P; Sonneveld P; Robak P; Semochkin S; Schey S; Yu X; Doerr T; Bensmaine A; Biyukov T; Peluso T; Zaki M; Anderson K; Dimopoulos M;
Lancet Oncol; 2019 Jun; 20(6):781-794. PubMed ID: 31097405
[TBL] [Abstract][Full Text] [Related]
17. Metronomic therapy is an effective salvage treatment for heavily pre-treated relapsed/refractory multiple myeloma.
Papanikolaou X; Szymonifka J; Rosenthal A; Heuck CJ; Mitchell A; Johann D; Keller J; Waheed S; Usmani SZ; Van Rhee F; Bailey C; Petty N; Hoering A; Crowley J; Barlogie B
Haematologica; 2013 Jul; 98(7):1147-53. PubMed ID: 23716540
[TBL] [Abstract][Full Text] [Related]
18. Efficacy and safety profile of long-term exposure to lenalidomide in patients with recurrent multiple myeloma.
Fouquet G; Tardy S; Demarquette H; Bonnet S; Gay J; Debarri H; Herbaux C; Guidez S; Michel J; Perrot A; Serrier C; Miljkovic D; Avet Loiseau H; Facon T; Hulin C; Leleu X
Cancer; 2013 Oct; 119(20):3680-6. PubMed ID: 23921945
[TBL] [Abstract][Full Text] [Related]
19. Carfilzomib-dexamethasone vs bortezomib-dexamethasone in relapsed or refractory multiple myeloma by cytogenetic risk in the phase 3 study ENDEAVOR.
Chng WJ; Goldschmidt H; Dimopoulos MA; Moreau P; Joshua D; Palumbo A; Facon T; Ludwig H; Pour L; Niesvizky R; Oriol A; Rosiñol L; Suvorov A; Gaidano G; Pika T; Weisel K; Goranova-Marinova V; Gillenwater HH; Mohamed N; Feng S; Aggarwal S; Hájek R
Leukemia; 2017 Jun; 31(6):1368-1374. PubMed ID: 28025582
[TBL] [Abstract][Full Text] [Related]
20. KD-PACE Salvage Therapy for Aggressive Relapsed Refractory Multiple Myeloma, Plasma Cell Leukemia and Extramedullary Myeloma.
Alsouqi A; Khan M; Dhakal B; Du L; Harrell S; Hari P; Cornell RF
Clin Lymphoma Myeloma Leuk; 2021 Aug; 21(8):526-535. PubMed ID: 33985931
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
